Skip to main navigation Skip to search Skip to main content

Summary of the International Society for Heart and Lung Transplantation consensus conference on emerging understanding of antibodies and antibody-mediated rejection in heart transplantation

  • Consensus Conference participants
  • Medical University of Vienna
  • University of Pittsburgh
  • University of Hamburg
  • University of North Carolina at Chapel Hill
  • University of Michigan, Ann Arbor
  • Sorbonne Université
  • University of Toronto
  • University of Schleswig-Holstein
  • Hospital Clínic i Universitari
  • New York University
  • University of Alberta
  • Duke University
  • St. Vincent's Hospital Sydney
  • University of California at Los Angeles
  • Vanderbilt University
  • Falls Church
  • Northwestern University

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

The understanding of circulating antibodies and their relationship to antibody-mediated rejection (AMR) has yet to be fully elucidated in heart transplantation. Circulating antibodies are important in both pretransplant and post-transplant. In the pretransplant period, the more antibodies detected in a patient awaiting heart transplantation often significantly reduces the chance of obtaining a compatible donor heart. In the post-transplant period, de novo antibody development against the donor heart remains a challenge to manage. In both pre- and post-transplant scenarios, it is not known what approach is optimal for treating these patients with circulating antibodies. To address these unmet needs, a consensus conference was organized on April 18, 2023, endorsed by the International Society for Heart and Lung Transplantation. The conference represented a collaborative multidisciplinary effort by experts in cardiothoracic transplantation from across the world to understand and discuss the optimum approach and treatment of circulating antibodies and AMR in heart transplant candidates and recipients. The conference served as a forum to better understand antibodies and AMR and their impact on transplant patients. The nature of this consensus is to prepare a platform and pave the way for further detailed studies. The findings and consensus statements are hereby presented.

Original languageEnglish
Pages (from-to)e1-e20
JournalJournal of Heart and Lung Transplantation
Volume44
Issue number8
DOIs
StatePublished - 1 Aug 2025

Bibliographical note

Publisher Copyright:
Copyright © 2025 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Keywords

  • antibodies
  • antibody-mediated rejection
  • biomarkers
  • clinical outcomes
  • heart transplantation

Fingerprint

Dive into the research topics of 'Summary of the International Society for Heart and Lung Transplantation consensus conference on emerging understanding of antibodies and antibody-mediated rejection in heart transplantation'. Together they form a unique fingerprint.

Cite this